Classes
DEA Class; Rx
Common Brand Names; Natrecor
- Natriuretic Peptides
Description
Indicated only for acute decompensated heart failure
Augments the normal physiologic response in heart failure; improves PCWP and CHF symptoms
Indications
Contraindications
Atrial/ventricular arrhythmias, constrictive pericarditis, restrictive or obstructive cardiomyopathy, pericardial tamponade, significant valvular stenosis, suspected low cardiac filling pressures
Hypersensitivity
Primary treatment for patients with cardiogenic shock
Persistent systolic BP <100 mm Hg
Adverse Effects
- Hypotension (4-35% )
- Serum creatinine raised (17-28%)
- Nausea (4-13% )
- Ventricular tachycardia (3-10% )
- Headache (7-9% )
- Dizziness (3-6% )
- Insomnia (2- 6% )
- Back pain (4%)
- Ventricular premature beats (3-4% )
- Anxiety (3%)
- Angina (2%)
- Atrial fibrillation (1% or greater )
- Atrioventricular node (1% or greater )
- Bradycardia (1%)
- Somnolence (1%)
- Tremor (1%)
- Hypersensitivity reaction
- Extravasation
Warnings
Hypotenstion effects may be additive when using other agents that cause hypotension
Potential for nephrotoxicity
Use only in hospital setting
Caution in patients with renal impairment
Pregnancy and Lactation
There are no data to assess a drug associated risk of major birth defects, miscarriage, or adverse maternal fetal outcomes with therapy use in pregnant women
There are no data on the presence of nesiritide in human or animal breast milk, or regarding the effect on the breastfed child, or on milk production
Maximum Dosage
0.03 mcg/kg/min IV continuous infusion, with cautious hemodynamic monitoring.
0.03 mcg/kg/min IV continuous infusion, with cautious hemodynamic monitoring.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
How supplied
Nesiritide
injectable solution
- 1.5mg/vial